Saracatinib Trial TO Prevent FOP — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Saracatinib Trial TO Prevent FOP — Stella

Recruiting

Back to Fibrodysplasia Ossificans Progressiva trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(3 sites)

Germany

Klinikum Garmish-Partenkirchen, Garmisch-Partenkirchen

Netherlands

Amsterdam University Medical Center, Amsterdam

United Kingdom

Royal National Orthopaedic Hospital, London

Key details

Phase

Safety & dosing

Sponsor

Amsterdam UMC, location VUmc

Collaborators

Royal National Orthopaedic Hospital NHS Trust, Klinikum Garmisch-Patenkirchen

Enrollment target

~20 participants

Started

August 2020

Primary completion

May 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 65 Years

Last updated May 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov